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Introduction {#sec1}
============

Patients with inflammatory bowel diseases (IBD) with long-standing and extensive colitis are at higher risk of developing a distinct type of colorectal cancer, termed colitis-associated cancer (CAC) ([@bib6], [@bib38]). Although CAC etiology is complex and still incompletely understood, compromised epithelial integrity and deregulated Toll-like receptors (TLRs)-mediated microbiota sensing are important risk factors ([@bib9]). Disruption of this microbiota sensing mechanism either at the receptor level or via downstream adaptor molecules, such as Myd88 ablation, results in increased production of pro-inflammatory cytokines and colitis development ([@bib37]), favoring CAC onset ([@bib26], [@bib39]).

Dysbiosis and abundance of specific microbiota members can also influence carcinogenesis. Genomic analysis of human CRC biopsies detected a high prevalence of bacterial species such as *Fusobacterium nucleatum* and *Bacteroides fragilis* and have the ability to aggravate tumor propensity in mice ([@bib24], [@bib45]). Consistently, blocking of TLR/MyD88-mediated sensing abrogated colorectal carcinogenesis ([@bib36]).

Regulation of NF-κB activity is essential to avoid spontaneous and prolonged inflammatory responses upon receptor binding. In mice lacking IκB kinase β (IKKβ), CAC susceptibility ([@bib14]) was attributed to enhanced NF-κB-mediated IL-6 production and activation of STAT3-dependent epithelial neoplastic changes ([@bib2]). Similarly, ablation of TLR4 or chemokine receptor signals results in impaired immune cell infiltration and protection of mice against CAC ([@bib35], [@bib22], [@bib12]). Consistently, lack of negative regulators of innate immune signals, such as A20, single immunoglobulin receptor related molecule (SIGIRR), and interleukin receptor associated kinase-M (IRAK-M), was shown to enhance susceptibility to CAC in both humans and mice ([@bib42], [@bib51], [@bib23], [@bib1]). In CAC, although epithelial changes are essential to promote colon cancer, immune cell recruitment into the inflamed mucosa fuels tumor growth through perpetuation of inflammation ([@bib14]). Regulatory T cells (Tregs) control intestinal inflammation, but their contribution in colorectal carcinogenesis remains elusive and controversial ([@bib49], [@bib25]).

Toll-interacting protein (Tollip) is an intracellular, ubiquitously expressed adaptor protein, initially described as a negative regulator of NF-κB signaling ([@bib5], [@bib4]). Upon activation of IL-1R, TLR2, and TLR4, Tollip recruits interleukin receptor associated kinase 1 (IRAK1) but inhibits its disassociation, depending on the stimulus strength, thus resulting in discontinuation of NF-κB pathway ([@bib4], [@bib5], [@bib52], [@bib1]). Tollip also regulates the turnover of ubiquitinated receptors, such as IL-1R and TGFβ-RI, through clathrin-mediated endosomal trafficking and sorting to late endosomes ([@bib3], [@bib53], [@bib1]).

We have previously shown that Tollip deficiency increases susceptibility of mice to a dextran sodium sulfate (DSS) colitis model ([@bib27]). Tollip ablation resulted in disruption of tight junctions and increased intestinal permeability upon acute DSS chemical injury, whereas non-hematopoietic expression of Tollip partially restored disease susceptibility ([@bib27]). Tollip has also been linked to human IBD as its gene lies within one of the IBD susceptibility loci ([@bib47], [@bib21]). In addition, Tollip expression was downregulated in biopsies from both active and inactive colonic segments from patients with ulcerative colitis (UC) and Crohn\'s disease (CD) compared with healthy subjects ([@bib11]).

Despite the demonstrated role of Tollip in colitis, its influence on inflammation-associated cancer remains unknown. In this study, we report that Tollip promotes colitis-driven carcinogenesis. We found that Tollip-deficient mice fail to mount efficient chronic inflammatory responses resulting in reduced tumor risk. Those global defects were also accompanied by qualitative changes in cellular composition with a reduction in tumor-infiltrating regulatory T cells.

Results {#sec2}
=======

Variable *Tollip* mRNA Expression in Patients with CAC {#sec2.1}
------------------------------------------------------

Although Tollip expression is decreased in sporadic colorectal cancer (CRC) adenomas ([@bib33]), there are no data available for human colitis-associated cancer (CAC) lesions. Given the link between inflammation and inflammation-driven cancer, we hypothesized that Tollip should be downregulated in CAC lesions. Therefore, we investigated *Tollip* mRNA expression in patients with IBD with active or quiescent UC or CD, as well as in CAC or sporadic CRC adenomas, compared with adjacent non-tumorous (NT) mucosal biopsies from sporadic CRC. Consistent with previous reports, we observed reduced *Tollip* mRNA expression in mucosa of patients with quiescent and active UC and CD compared with the control NT mucosal biopsies ([Figure 1](#fig1){ref-type="fig"}). Moreover, *Tollip* expression was downregulated in paired mucosal samples of sporadic CRC adenomas compared with NT normal adjacent mucosa ([Figure 1](#fig1){ref-type="fig"}). Surprisingly, *Tollip* expression in patients with CAC was variable and not significantly decreased, as we initially hypothesized. *Tollip* expression was higher in 2/6 CAC samples, histologically characterized as adenocarcinoma, compared with 4/6 CAC samples of low-grade dysplastic lesions, as well as with patients with quiescent and active UC and CD, whereas it was comparable with NT normal adjacent mucosa biopsies ([Figure 1](#fig1){ref-type="fig"}). In summary, Tollip expression is differentially regulated in CAC lesions compared with sporadic adenomas. We decided to further investigate the role of Tollip in an *in vivo* mouse model of chronic colitis-associated cancer onset, in which adenomas do not develop a differential dysplastic grade.Figure 1Tollip Expression in Biopsies from Patients with IBD and Colon CancerqRT-PCR analysis of *Tollip* mRNA expression relative to *Gapdh* in active and inactive gut segments from patients with UC and CD. n = 14 and n = 8 for UC and n = 15 and n = 10 for CD, respectively. Tollip expression was also assessed in biopsies from adenomas developed in patients with IBD (CAC, n = 6) and sporadic colorectal cancer (CRC, n = 10). As control, RNA extracts from the non-tumoral colon adjacent to the CRC (n = 10) were taken. Data are mean ± SEM. Differences were analyzed by one-way ANOVA test for CAC versus non-active UC and CAC versus non-active CD; p = 0.0497 and p = 0.0458, were calculated, respectively. Differences between CRC and NT were analyzed by Wilcoxon matched-pairs test, p = 0.0020. \*p \< 0.05, \*\*p \< 0.01.

Tollip Ablation Is Protective against Colitis-Associated Cancer {#sec2.2}
---------------------------------------------------------------

To decipher the role of Tollip in CAC and avoid the variability introduced by human biopsies, we employed a CAC model in mice lacking Tollip expression. Tollip^*−/−*^ and wild-type (WT) littermates were challenged with the azoxymethanone (AOM)/dextran sodium sulfate (DSS) model to recapitulate CAC development ([Figure 2](#fig2){ref-type="fig"}A). Adenoma growth and development were monitored by mouse colonoscopy at day 63 ([Figures 2](#fig2){ref-type="fig"}A and 2B). We observed significantly fewer adenomas and reduced endoscopic tumor scores ([@bib100]) in the AOM/DSS-exposed Tollip^*−/−*^ compared with WT mice, indicating that Tollip ablation resulted not only in reduced tumor incidence but also in smaller lesions ([Figures 2](#fig2){ref-type="fig"}B and 2C). Consistently, macroscopic examination of the excised colons demonstrated reduced tumor number upon Tollip ablation ([Figures 2](#fig2){ref-type="fig"}D and 2E). We also observed a significant increase in small (\<2 mm) lesions and decrease in larger (2--4 mm) lesions in Tollip^*−/−*^ compared with WT mice ([Figure 2](#fig2){ref-type="fig"}F), indicating that Tollip ablation results in the formation of smaller adenomas, in accordance with the observed endoscopic score ([Figure 2](#fig2){ref-type="fig"}C). Histological analyses confirmed the development of adenomatous AOM/DSS-induced polyps ([Figure 2](#fig2){ref-type="fig"}G), whereas frequency of dysplastic low-high grade or adenocarcinoma development was similar between Tollip^*−/−*^ and WT mice ([Figure 2](#fig2){ref-type="fig"}H). These data, together with our previous findings, suggest that Tollip has a dual role in favoring CAC development despite being protective against acute colitis.Figure 2Tollip Deficiency Attenuates Colitis-Associated Carcinogenesis(A) Tollip^*−/−*^ and WT littermates C57BL/6 mice received a single intraperitoneal AOM injection (10 mg/kg) followed by three cycles of 2.5% DSS in drinking water. Unchallenged Tollip^*−/−*^ and WT littermates were used as controls. On day 63, mice were subjected to colonoscopy to assess adenoma development and size.(B) An endoscopic score was determined according to a standardized grading system ([@bib100]). Representative endoscopic images from AOM/DSS exposed WT (upper panel) and Tollip^*−/−*^ littermates at day 63. Tumors are depicted with blue arrows and ulcer formation with green arrowheads.(C) Endoscopic tumor number and score in AOM/DSS-exposed WT and Tollip^*−/−*^ littermates and unchallenged animals. Each dot represents data from an individual mouse. Data are mean ± SEM; n = 3--5 for unchallenged and n = 8--14 for treated groups. Differences were analyzed by Mann-Whitney test. p = 0.0318, p = 0.0106, for tumor number and score, respectively.(D) Macroscopic evaluation of adenomatous lesions in excised colons from treated Tollip^*−/−*^ and WT littermates.(E and F) Quantification of overall macroscopic tumor number and size in AOM/DSS exposed Tollip^*−/−*^ and WT littermates. Data are mean ± SEM; n = 8--14. Differences were analyzed by Mann-Whitney test, p = 0.0299 for macroscopic tumor number. Differences were analyzed with multiple t tests for macroscopic tumor size; p = 0.02 and p = 0.0001 for \<2 and 2--4 mm, respectively.(G) Histological evaluation of tubular adenomas formation by hematoxylin and eosin staining (H&E) in paraffin-embedded colons of Tollip WT (i--iii) and Tollip^*−/−*^ treated mice **(iv--vi)** in increasing magnifications of 10×, 20×, and 40×. Scale bars: 100 μm.(H) Histopathological score of adenomas in H&E staining of paraffin-embedded colons, LG, low-grade dysplasia; HG, high-grade dysplasia; ADK, adenocarcinoma. Differences were analyzed by two-tailed unpaired t test. Data are mean ± SEM. n = 8--19. ns p \> 0.5, \*p \< 0.05, \*\*\*p \< 0.001.

Tollip Deficiency Is Associated with Reduced Cell Turnover in Colonic Adenomas {#sec2.3}
------------------------------------------------------------------------------

Given the protective role of Tollip in colonic epithelium during acute inflammation ([@bib27]), we hypothesized that reduced tumor incidence in Tollip^*−/−*^ mice could be related to defects in cell turnover rates. To address this hypothesis, we assessed apoptosis during tumor initiation and late tumor stage in the CAC model. At the beginning of AOM/DSS treatment (day 8) we observed a significant increase in epithelial apoptotic Tunel^+^ cells in Tollip-deficient colons ([Figures 3](#fig3){ref-type="fig"}A and 3B). However, at late tumor stage (day 63) the apoptotic index was significantly decreased in both Tollip-deficient adenomas ([Figures 3](#fig3){ref-type="fig"}C and 3E) and crypts of adjacent non-adenomatous mucosa of Tollip^*−/−*^-treated animals compared with WT-treated mice ([Figures 3](#fig3){ref-type="fig"}D and 3F). Notably, the density of apoptotic cells was higher at the tip of colonic crypts in acute inflammation/early stage carcinogenesis on day 8 ([Figure 3](#fig3){ref-type="fig"}A), whereas analysis of late-stage carcinogenesis on day 63 showed a shift toward the lamina propria ([Figure 3](#fig3){ref-type="fig"}D). The apoptotic index was similar in unchallenged mice ([Figure 3](#fig3){ref-type="fig"}F) and our multi-screen gene analysis showed a downregulation of additional apoptosis-related genes in Tollip-deficient adenomas compared with WT ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We also observed a significantly reduced proliferative index in Tollip-deficient compared with WT adenomas ([Figure 3](#fig3){ref-type="fig"}G). We next examined STAT-3 activation ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D), along with important upstream and downstream targets involved with neoplastic properties of the STAT3 pathway ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Immunohistochemical analyses of the active form of STAT3 (P-STAT3) ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and relative P-STAT3 expression levels, although variable, were comparable between Tollip^*−/−*^ and WT adenomas ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D) and in colons of untreated animals ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Similarly, *Bcl-xL*, *c-myc*, *Bax*, *IL-6*, and *IL-11* mRNA expression was comparable between Tollip^*−/−*^ and WT adenomas ([Figure S1](#mmc1){ref-type="supplementary-material"}E). In unchallenged Tollip^*−/−*^ mice, *Bcl-xL* and *c-myc* mRNA expression was lower in whole colon homogenates compared with WT mice, indicating that the mucosal environment upon homeostatic conditions tends to be skewed toward a pro-apoptotic response ([Figure S1](#mmc1){ref-type="supplementary-material"}E). However, this was not correlated with an impaired STAT3 signaling during tumorigenesis as both total and P-STAT3 protein abundance were comparable in Tollip^*−/−*^ and WT adenomas, as well as in unchallenged mucosa ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D). Taken together, these results indicate that Tollip deficiency induces pronounced epithelial apoptosis upon early tumorigenesis but, in the late tumor stage, Tollip deficiency results in retarded development and progress of adenomas with low turnover rates.Figure 3Tollip-Deficient Adenomas Present Reduced Proliferative and Apoptotic Indexes(A) Tollip^*−/−*^ and WT C57BL/6 littermates received a single i.p. AOM injection (10 mg/kg). After 5 days mice received oral treatment of 2.5% DSS in the drinking water and were euthanized on day 8; n = 5--6 mice. Cells apoptosis was quantified via immunofluorescent analysis of TUNEL^+^ cells on day 8. DAPI was used for nuclear staining. Scale bars: 100 μm. Insets show a magnified view of the TUNEL^+^ apoptotic cells.(B) Quantification of TUNEL^+^ apoptotic cells in 20× field for at least three representative pictures/mouse. Data are mean ± SEM. Differences were evaluated with Mann-Whitney test. p = 0.0001.(C and D) (C) Immunofluorescent evaluation of apoptosis by TUNEL staining in adenomas and (D) normal adjacent mucosa of AOM/DSS-exposed mice. DAPI was used for nuclear staining. Scale bars: 100 μm. Insets show a magnified view of the TUNEL^+^ apoptotic cells.(E and F) (E) Quantification of TUNEL^+^ apoptotic cells in adenomas and (F) normal adjacent mucosa of treated as well as in colons of untreated mice in 10× field view for at least three representative pictures per mouse. Data are mean ± SEM. n = 5--14. Differences were analyzed by Mann-Whitney test. p = 0.0059 and p \< 0.0001 for adenomas and normal mucosa crypts, respectively.(G) Representative immunohistochemical Ki67 and nuclear staining with hematoxylin in adenomas of paraffin-embedded colons from AOM/DSS-treated mice. Scale bars: 100 μm. Analysis of proliferative index by measuring the percentage of surface of Ki67/nuclear staining ratio specifically for the adenomas by ImageJ algorithm Immunoratio. Counting was performed in 10× field view for at least three representative pictures/adenoma. Data are mean ± SEM. n = 5--7 mice and n = 21--34 adenomas. Differences were analyzed by Mann-Whitney test, p = 0.0357. \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001.

Reduced Cancer Risk in Tollip-Deficient Animals Is Not Associated with Changes in Gut Microbial Composition {#sec2.4}
-----------------------------------------------------------------------------------------------------------

Given the role of Tollip as regulator of the Toll/IL-1R signaling and the implication of several of those pathways in microbiota shaping, we hypothesized that changes in gut microbial composition might account for reduced cancer occurrence in Tollip-deficient mice. We performed 16S rRNA amplicon sequencing on feces of co-housed Tollip^*−/−*^ and WT littermates prior and after AOM/DSS treatment. There was no difference in microbiota diversity between the two groups both at baseline ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and after treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}B). As inflammation-induced colon tumorigenesis has been linked with shifts in microbiota composition, we next addressed differences in microbiota composition between Tollip^*−/−*^ and WT littermates. There were no differences in overall microbiota composition both before (ANOSIM p = 0.474) ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and following AOM/DSS treatment (ANOSIM, p = 0.5083, [Figure S2](#mmc1){ref-type="supplementary-material"}D). The relative abundance of bacterial taxa at the phylum level was comparable between Tollip^*−/−*^ and WT mice both before and after treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Finally, we evaluated changes in specific bacterial taxonomic groups using differential abundance testing. We detected a minor enrichment of unclassified genus of *Peptococcaceae* (p = 0.019, LDA score = 1.5326) in WT mice and *Rikenellaceae* family of also unclassified genera and of unclassified families within the *Bacteroidales* order (p = 0.028) in stools of Tollip^*−/−*^ mice (p = 0.034, LDA score = 2.1055 and 2.0850) ([Figure S2](#mmc1){ref-type="supplementary-material"}F) following AOM/DSS treatment. Finally, AOM/DSS treatment itself led to a decrease in families within the *Proteobacteria* phylum, independently of genotype ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Altogether, these data demonstrate that reduced tumor incidence upon Tollip deficiency does not correlate with a tumor-protective shift in microbiota diversity or global composition.

Tollip Modulates Migration Patterns and Cell Infiltration in Colonic Mucosa {#sec2.5}
---------------------------------------------------------------------------

We next aimed to investigate whether Tollip ablation could influence mucosal immune inflammation-related cell composition. Multi-gene RNA screening in healthy colons of unchallenged animals demonstrated a significant reduction in L-selectin (*Cd62L)* mRNA expression ([Figure 4](#fig4){ref-type="fig"}A), an adhesion molecule known to regulate trafficking of naive or central memory T (T~N~ or T~CM~) cells from blood to secondary lymphoid organs ([@bib28]). We also observed a non-significant reduction in several T cell homing markers such as *Cd44*, *Il7r*, and *Ccr7*, as well as the integrins *Itgβ2* and *Itgα4* that form the heterodimers LFA-1 and the gut-homing α4β7 ([@bib28]), respectively ([Table S1](#mmc1){ref-type="supplementary-material"}). Next, we assessed whether T cell recruitment to the healthy gut mucosa was influenced by Tollip ablation under basal conditions. We found no differences in the CD3^+^/CD4^+^/CD8^+^ T cell abundance in the colons of unchallenged mice ([Figure 4](#fig4){ref-type="fig"}B). However, investigation of the activation status of Tollip-deficient T cells in the periphery demonstrated a significant increase in the percentage of CD8^+^ CD44^-^ CD62L^+^ T~N~ (naive) cells in spleen, blood, and peripheral lymph nodes (pLNs) ([Figures 4](#fig4){ref-type="fig"}C and 4D). The percentages of CD8^+^ CD44^hi^ CD62L^−^ T effector (T~eff~) ([Figures 4](#fig4){ref-type="fig"}C and 4D) and CD4^+^ CD44^-^ CD62L^+^ T~N~ and CD4^+^ CD44^hi^ CD62L^−^ T~eff~ cell were comparable between Tollip^*−/−*^ and WT mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Interestingly, we also observed a significant reduction in *Ccr5* mRNA expression in Tollip^*−/−*^ mice ([Figure 4](#fig4){ref-type="fig"}A, [Table S1](#mmc1){ref-type="supplementary-material"}), a chemokine receptor known to mediate the recruitment of immune cells upon inflammatory conditions ([@bib15]). Collectively, these results suggest that Tollip deficiency favors naive cell accumulation in peripheral lymphoid organs upon homeostatic conditions.Figure 4Tollip Deficiency Alters Migration Patterns upon Homeostatic Conditions(A) Volcano plot depicts differential gene expression in colonic mucosa of untreated Tollip^*−/−*^ and WT littermates (data obtained from three biological replicates per group).(B) Flow cytometry analysis of colonic lamina propria T cells frequency and absolute cell numbers in untreated Tollip^*−/−*^ and WT littermates. Data are mean ± SEM. n = 5--7 mice.(C) Representative FACS plots of CD44^+^ and CD62L^+^ T cells frequencies in spleen and blood, pre-gated on CD8^+^ T lymphocytes.(D) Flow cytometry analysis of naive and effector CD8^+^ T cells frequencies isolated from peripheral (pLN) and mesenteric (mLN) lymph nodes, spleen, and blood. Data are mean ± SEM; n = 4--5 mice. Differences were analyzed by one-way ANOVA test. p = 0.045, p = 0.0031, and p = 0.0015 values were calculated for pLN, spleen, and blood, respectively. \*p \< 0.05, \*\*p \< 0.01.

Tollip Deficiency Impedes Infiltration of CD4+ and Regulatory T Cells in Adenomas {#sec2.6}
---------------------------------------------------------------------------------

We next questioned whether the altered cell trafficking noted upon Tollip ablation during homeostatic conditions would impede immune cell accumulation and attenuate inflammatory responses upon AOM/DSS challenge. Despite Tollip commonly being described as a negative regulator ([@bib52]), several pro-inflammatory genes were downregulated in Tollip-deficient compared with WT adenomas ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Investigation of other inflammatory indexes, such as colonic shortening, was moderate in treated Tollip^*−/−*^ mice compared with the significantly reduced colon length observed in WT mice ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We also noticed a significant reduction in CD45^+^ cells frequency and absolute number infiltrates in Tollip-deficient adenomas compared with WT ([Figure S4](#mmc1){ref-type="supplementary-material"}C). In addition, we also observed a prominent reduction of IFNγ- and TNFα-producing inflammatory cells infiltration into colons of challenged Tollip^*−/−*^ mice compared with WT mice ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Collectively, these data suggest that Tollip aggravates inflammatory responses at late tumor stage development (day 63), whereas no differences in CD45^+^ frequency and infiltration were observed in pLNs, mLNs, ileum, and spleen ([Figure S5](#mmc1){ref-type="supplementary-material"}A).

Given our observation of reduced immune cell infiltration in Tollip^*−/−*^ adenomas ([Figure S4](#mmc1){ref-type="supplementary-material"}C), we further questioned whether reduced CD45^+^ cell accumulation was associated with defects in CD3^+^ T cell infiltration. As expected, we observed a marked colon-specific decrease in the frequency and number of CD3^+^ T cell infiltrates in *Tollip*^*−/−*^ compared with WT adenomas ([Figure 5](#fig5){ref-type="fig"}A). This decrease was mainly due to reductions in CD4^+^ T cells frequency and infiltrates ([Figure 5](#fig5){ref-type="fig"}A). Importantly, this defect was only seen in the colonic adenomas but not in peripheral lymphoid organs ([Figure S5](#mmc1){ref-type="supplementary-material"}B), suggesting that the observed changes are restricted to the mucosal environment during carcinogenesis.Figure 5Tollip Deficiency Impairs T Regulatory Cells Accumulation into Colitis-Associated Adenomas(A) Representative FACS plots of tumor-infiltrating T cells and analysis of CD3^+^, CD4^+^, and CD8^+^ T cells frequencies and absolute cell numbers isolated from adenomas of Tollip^*−/−*^ and WT mice. Data are mean ± SEM; n = 6 mice. Differences were analyzed by multiple t test. p = 0.03 and p = 0.003 values were calculated for CD3^+^ and CD4^+^ T cell frequencies, and p = 0.004 and p = 0.004 values were calculated for CD3^+^ and CD4^+^ T absolute cells numbers, respectively.(B) Cell type mRNA profiling scores for CD45^+^, T cells, and T regulatory (Treg) cells are calculated for adenomas and colon mucosa of treated and untreated Tollip^*−/−*^ and WT mice.(C) Volcano plot depicts differential gene expression in adenomas of AOM/DSS-exposed Tollip^*−/−*^ versus WT littermates (data obtained from three biological replicates per group).(D) Relative mRNA expression of *Foxp3*, *TGF-β*, and *IL-10* analyzed by real-time PCR. *Gadph* was used as a house keeping gene. Data are mean ± SEM; n = 5--19 samples. Differences were analyzed by two-tailed unpaired t test. p = 0.0228 for colons of untreated mice and p = 0.0027 *Foxp3* values for adenomas were calculated and p = 0.0317 for *TGF-β* for adenomas.(E) Immunoblot analysis for phosphorylated Smad-2 (P-Smad-2, band at 60kD) and total Smad-2 (band at 60kD) protein extracted from whole colon homogenates from tumors (T) of both treated mice. β-Actin (at 42 kD) was used as a loading control. The pre-stained protein ladder appears before the protein bands of interest. The molecular bands of 100, 55, and 35 kD are noted in the pre-stained protein ladder that appears before the protein bands of interest. The same nitrocellulose membrane was used for the immunoblotting of all three markers.(F) Representative FACS plots of tumor-infiltrating CD4^+^ CD25^+^ Foxp3^+^ T regulatory cells and analysis of CD4^+^ Foxp3^+^ and CD4^+^ CD25^+^ Foxp3^+^ Treg cells frequencies and absolute numbers isolated from adenomas of Tollip^*−/−*^ and WT mice. Data are mean ± SEM; n = 6 mice. Differences were analyzed by t test. p = 0.023 and p = 0.0041 values were calculated for Treg frequencies and absolute cell numbers, respectively. \*p \< 0.05, \*\*p \< 0.01.

To further investigate this reduced colon-specific infiltration of inflammatory cells, we performed a multi-screen RNA analysis. In line with the flow cytometry data ([Figure S4](#mmc1){ref-type="supplementary-material"}C), a lower *CD45*^*+*^ mRNA cell score was predicted for the challenged Tollip^*−/−*^ compared with WT mice ([Figure 5](#fig5){ref-type="fig"}B), indicative of attenuated inflammatory responses. *Tollip* expression was used as internal control and was, as expected, not expressed in Tollip-deficient samples ([Figure 5](#fig5){ref-type="fig"}C). We observed a non-significant trend of reduced expression of genes relevant to the immune cells homing to inflammatory sites in colons of treated Tollip^*−/−*^ versus WT mice ([Table S2](#mmc1){ref-type="supplementary-material"}). Additionally, we found a significant reduction in expression of three key T cell receptor signaling-associated genes in Tollip-deficient adenomas ([@bib44], [@bib19], [@bib46]), namely, *Ctla4*, *Cd27*, and *Ptpn22* ([Figure 5](#fig5){ref-type="fig"}C, [Table S2](#mmc1){ref-type="supplementary-material"}).

*Ctla4* is a costimulatory molecule that prevents excessive T cell activation upon TCR ligation. It has also been shown to be constitutively expressed on regulatory T cells ([@bib40]). Given the observed reduction in *Ctla4* expression in Tollip-deficient adenoma, we hypothesized that defects in immunosuppressive pathways could be observed upon Tollip ablation. Indeed, cell type mRNA profiling suggested reduced T lymphocytes and regulatory T cell abundance in both whole colon homogenates of unchallenged and adenomas of AOM/DSS-challenged Tollip^*−/−*^ mice ([Figure 5](#fig5){ref-type="fig"}B). Accordingly, we noted a significant reduction in *Foxp3* mRNA expression in both healthy mucosa and adenomas of Tollip^*−/−*^ compared with WT mice ([Figure 5](#fig5){ref-type="fig"}D). Furthermore, *TGF-β* but not *Il10* mRNA expression was downregulated in Tollip-deficient adenomas ([Figure 5](#fig5){ref-type="fig"}D). Consistently, we found a significant decrease in phospho-Smad2 and total Smad2 protein abundance that are known downstream effectors of *TGF-β* ([Figure 5](#fig5){ref-type="fig"}E). Altogether, those data demonstrate that Tollip ablation leads to reduced immunoregulatory T cell accumulation and blunted TGF-β/TGFβR-mediated responses.

Finally, we sought to determine the Treg frequencies and cell numbers systemically ([Figure S5](#mmc1){ref-type="supplementary-material"}C) and in adenomas ([Figure 5](#fig5){ref-type="fig"}F). Indeed, we wanted to examine whether reduced CD3^+^ T cell accumulation in adenomas was also associated with an imbalance between effector and regulatory T cells. In association with our prior results, we detected reduced CD4^+^ Foxp3^+^ and CD4+ Foxp3^+^ CD25^+^ frequencies and cell numbers infiltrating Tollip-deficient adenomas compared with WT ([Figure 5](#fig5){ref-type="fig"}F). Conversely, no differences in Treg frequency or cell number were noted in other lymphoid organs ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Altogether, our data show that Tollip deficiency leads to reduced CD3^+^ T cell accumulation in colonic adenoma together with a local imbalance between effector and regulatory T cells.

Collectively, these data suggest that decreased adenoma risk in Tollip-deficient mice is associated with impeded immune cell infiltration and attenuated inflammatory responses together with abrogated Treg infiltration.

Discussion {#sec3}
==========

Aberrant activation of TLR and NF-κB signaling modifies risk of colitis and cancer development in mice ([@bib42], [@bib51], [@bib23], [@bib1]). Tollip is an intracellular adaptor able to negatively regulate IL-1R and TLR2/TLR4-mediated NF-κB activation and to promote tolerance in intestinal epithelial cells (IECs) ([@bib4], [@bib5], [@bib31]). We hypothesized that Tollip deficiency would promote CAC risk, based on our previous findings ([@bib27]) and what had been previously reported on other innate negative regulators ([@bib39], [@bib51], [@bib1]). However, we observed that Tollip^*−/−*^ mice were partially protected against CAC and that Tollip expression tended to be downregulated in dysplastic lesions from patients with UC.

Although prominent epithelial damage was observed early on the AOM/DSS regime, this only evolved to blunted tumor development characterized by reduced cell turnover. This could be in part due to a reduced number of surviving epithelial cells subjected to AOM-induced mutagenesis. Although increased epithelial apoptosis activates STAT3-mediated pro-repair and neoplastic responses ([@bib2]), histologically we did not find any difference in STAT3 protein expression. Similarly, analysis of STAT3 activation pathway showed that it remained unchanged upon Tollip deficiency.

Following epithelial destruction and microbial incursion, infiltrating leukocytes not only support anti-microbial responses but also fuel tumorigenesis via excessive cytokine and growth factor production ([@bib9], [@bib48]). Interestingly, Tollip deficiency led to poor leukocyte recruitment to tumoral tissues despite prominent epithelial disruption at early stages of acute DSS-induced injury. Our findings correlate with prior reports on TLR4 signaling, in which Tollip actively participates. Indeed, TLR4 deficiency promoted colitis induction but attenuated tumor development and growth due to reduced leukocyte infiltration into inflamed mucosa ([@bib13], [@bib12]).

Consistently, Diao and colleagues reported decreased numbers of Ly-6G^+^ cells infiltrating the colonic mucosa of Tollip^*−/−*^ mice upon acute colitis. In addition, Tollip-deficient CCR5^+^ neutrophils accumulated in the blood due to decreased chemotactic receptor FPR2 levels, indicating defective migration of these cells into inflamed colonic mucosal sites ([@bib10]). CCR5 is an inflammatory chemokine receptor enabling recruitment of diverse immune cell types ([@bib15]). In a phase I clinical trial of metastatic colorectal cancer, drug-induced blockade of CCR5+CD4^+^ and CD8^+^ lymphocyte infiltration with maraviroc reduced interaction of lymphocytes with MΦs, leading to reduced inflammation and better clinical responses ([@bib17]). Ablation of chemokine receptors, such as CCR2 and CXCR2, was shown to severely abrogate leukocyte infiltration, resulting in reduced inflammation-driven colon cancer ([@bib34], [@bib35], [@bib22]). Notably, we demonstrated a pronounced decrease in *Ccr5* expression in the colonic mucosa of unchallenged Tollip ^*−/−*^ mice, indicating a potential correlation between Tollip-Ccr5 expression and modulation of leukocytes trafficking, which deserves further study.

Tollip ablation influenced not only chemokine receptors expression but also lymphocyte homing molecules causing altered T cells migratory patterns. As such, a pronounced *Cd62l* mRNA decrease in colonic mucosa correlated with increased accumulation of naive CD8^+^ CD62L^+^ T cells in the blood of Tollip^*−/−*^ unchallenged mice. This effect was even more pronounced in Tollip-deficient adenomas, where we observed a prominent reduction in CD3^+^ T lymphocyte infiltrates. This colon-specific reduction was restricted to colorectal carcinogenesis, as it could not be detected in peripheral lymphoid organs or upon homeostatic conditions. Remarkably, decreased CD3^+^ T lymphocyte infiltration was mainly due to reduced CD4^+^ Foxp3^+^ Treg cells recruitment in the tumor microenvironment. In line with this observation, we observed a significant decrease in *Ctla4* mRNA expression in Tollip-deficient adenomas, a receptor expressed on Treg cells. Finally, defects in TGFβR signaling activation further argued for reduced immune-suppressive responses in tumor microenvironment upon Tollip ablation. We suggest that, already during homeostasis, Tollip ablation predisposes leukocytes accumulation in the periphery. In addition, Tollip deficiency also affects leukocyte recruitment, predominantly Treg cells, to adenomatous lesions.

Although Treg cells are key factors of intestinal homeostasis and protect against colitis ([@bib29], [@bib44]), their role in colitis-induced cancer was recently associated with poor prognosis ([@bib32]). As such, depletion of Tregs during acute CAC resulted in increased intestinal inflammation, whereas ablation of Tregs at late CAC state promoted CD8^+^-induced IFNγ/granzyme B antitumoral responses, resulting in hindered tumor progress ([@bib32]). Hence, our observations support the concept that reduced Treg infiltration upon Tollip ablation into the inflamed colonic mucosa might underlie early CAC events by facilitating epithelial destruction, whereas attenuated cell infiltration, due to Tollip ablation, on late CAC phase seems to play a protective role, resulting in reduced immune suppressive responses and partial protection from CAC onset and development.

The exact molecular mechanisms through which Tollip may alter leukocytes migratory capacity remains unknown. Several studies have shown that Tollip promotes endosomal trafficking of receptors for either lysosomal degradation or nuclear translocation ([@bib3], [@bib53], [@bib7]). As such, Tollip deficiency resulted in impaired trafficking and accumulation of IL-1R in late endosomes ([@bib3]). Therefore, we hypothesize that Tollip deficiency may impair endosomal trafficking of several chemokine receptors and T cell homing factors, such as CCR5 and CD62L.

Altogether, our human and murine data indicate that Tollip plays a dual role in being protective against colitis while exacerbating colitis-induced cancer in mice. Our findings implicate Tollip in the expression of several homing/trafficking molecules of relevance to anti-tumoral immunity, including T lymphocytes and Treg subset infiltration. Thus, shifts in anti-tumoral immunity profile together with defects in TGFβR signaling underlie partial protection from colitis-associated cancer. Future studies should assess the role of Tollip in the turnover of inflammatory and suppressive receptors, as well as in leukocyte migration to inflammatory and cancerous sites.

Limitations of the Study {#sec3.1}
------------------------

Our initial findings using human samples were only exploratory due to limited sample size. This was in part due to the rare incidence of colitis-associated cancer in human subjects and also to a limited number of patients screened in the GETAID cohort. In addition, samples obtained from the SIBDCS were only taken in active versus inactively inflamed colon segments prompting us to complete our dataset with samples coming from different sources.

To explore the mechanisms underlying colitis-associated cancer development, we employed the widely accepted and established AOM/DSS mouse model. Although this model is thought to most closely reflect human CAC development, kinetics of adenoma development is more rapid in mice than in humans, putting some limitations in the analyses of cell-recruitment dynamics in tumors. Moreover, AOM/DSS-treated mice mostly develop non-invasive adenomas, whereas in humans the carcinogenic process may evolve to a fully blown invasive adenocarcinoma. As Tollip expression may be different between low-grade and advanced adenomas, more detailed analyses could not be done in the mouse setting.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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